dimecres, 3 d’abril del 2019

FDA accepts second application for Ocular Therapeutix’s drug-delivering implant

Ocular Therapeutix logo

Ocular Therapeutix (NSDQ:OCUL) said today that the FDA has accepted a new supplemental New Drug Application for its Dextenza, an ocular insert designed to release dexamethasone to relieve pain following ophthalmic surgery.

The Bedford, Mass.-based company’s device is designed to deliver drugs for up to 30 days following treatment in a physician’s office. Ocular Therapeutix is positioning its product as a way to eliminate the current standard of care for post-surgical pain – topical steroid eye drops.

Read the whole story on our sister site, Drug Delivery Business News



from MassDevice https://ift.tt/2TYzNlC

Cap comentari:

Publica un comentari a l'entrada